Show all news
  • 2017/745 (EU)
  • Borderline product
  • Demarcation
  • MDR
  • Medical Device
  • Medical Device Regulation
  • Medicinal product
  • MPG
  • Substance-derived medical devices

Medicinal product or medical device? – Webinar

Mar  8, 2021

 March 30, 2021, 3 pm cet

In which category does my product belong? This is often a non-trivial question.

In theory, medicinal products and medical devices can be very appropriately distinguished in terms of their modes of action and thus their medical purposes: while medicinal products exert their effect in a pharmacological, immunological or metabolic manner, medical devices achieve their effect predominantly by mechanical, physical, chemical, physicochemical or similar means. In practice, however, it becomes apparent that the determination of the product category is not always trivial. The routes to market approval for drugs and medical devices are basically comparable, not least to ensure a comparable level of efficacy and safety, but in their details they differ considerably.

The proof of safety and efficacy that has to be provided differs, and this has a significant impact on the time and budget required before the products can be launched on the market. With the new Medical Device Regulation (MDR) 2017/745 (EU), which comes into force in May, the demarcation becomes more blurred, especially for material medical devices, and the effort for the manufacturer increases significantly once again. This poses major challenges for medical device companies in particular.

In this webinar, we would like to shed light on clinical development according to AMG and MPG (MDD) / MDR, with a special focus on products for which it is often difficult to clearly assign them to one of the two regulatory dimensions.

We would like to inform about which products this concerns and how an incorrect classification can be avoided. To this end, we will provide relevant examples from practice and address questions from the audience at the end of the webinar.

Our experts in this webinar are:

Bernd Brormann, Senior Director Clinical Research & CRO Services

Ralf G. Sibbing, Managing Partner TentaConsult Pharma & Med GmbH

Participation in the webinar is free of charge.

60 minutes

Register here!

Besuchen Sie uns auf LinkedIn    

We Value Your Privacy
We use cookies on our website. Some of them are essential, while others help us to analyze how this website is being used and to allow you to contact us through our website, i.e. use the chat widget. You can change your decision at any time.
We Value Your Privacy
We use these technologies to analyze how this website is being used.
Name Google Analytics, Google Tag Manager
Provider Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland
Purpose Cookie by Google used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy Policy
Cookie Name _ga, _gat, _gid
Cookie Expiry 2 years
Customer Interaction
These technologies will allow you to contact us through our website, i.e. use the chat widget.
Name LiveChat
Provider LiveChat Software S.A., ul. Zwycięska 47, 53-033 Wroclaw, Poland
Purpose Communication with clients via online chat using the API of the chat service LiveChat.
Privacy Policy
Cookie Name __lc_cid, __lc_cst
Cookie Expiry 2 years
Technologies required to enable the core functionality of this website.
Name Cookie Consent
Provider Owner of this website, Imprint
Purpose Saves the visitors preferences selected in the cookie banner.
Cookie Name ws_cookie_consent
Cookie Expiry 1 year